MA37928A1 - Tri(hétéro)arylpyrazoles et leur utilisation - Google Patents

Tri(hétéro)arylpyrazoles et leur utilisation

Info

Publication number
MA37928A1
MA37928A1 MA37928A MA37928A MA37928A1 MA 37928 A1 MA37928 A1 MA 37928A1 MA 37928 A MA37928 A MA 37928A MA 37928 A MA37928 A MA 37928A MA 37928 A1 MA37928 A1 MA 37928A1
Authority
MA
Morocco
Prior art keywords
arylpyrazoles
hetero
tri
diseases
prophylaxis
Prior art date
Application number
MA37928A
Other languages
English (en)
Inventor
Burkhard Klenke
Steffen Wildum
Astrid Wendt
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48986151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37928(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA37928A1 publication Critical patent/MA37928A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La présente invention concerne de nouveaux tri(hétéro)arylpyrazoles, leur procédé de production, leur utilisation pour le traitement et/ou la prophylaxie de maladies, ainsi que leur utilisation pour la fabrication de médicaments destinés au traitement et/ou à la prophylaxie de maladies, notamment de maladies rétrovirales, chez les hommes et/ou les animaux.
MA37928A 2012-08-17 2013-08-16 Tri(hétéro)arylpyrazoles et leur utilisation MA37928A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012016908.6A DE102012016908A1 (de) 2012-08-17 2012-08-17 Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
PCT/EP2013/067201 WO2014027112A1 (fr) 2012-08-17 2013-08-16 Tri(hétéro)arylpyrazoles et leur utilisation

Publications (1)

Publication Number Publication Date
MA37928A1 true MA37928A1 (fr) 2017-11-30

Family

ID=48986151

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37928A MA37928A1 (fr) 2012-08-17 2013-08-16 Tri(hétéro)arylpyrazoles et leur utilisation

Country Status (27)

Country Link
US (1) US9249148B2 (fr)
EP (1) EP2885300A1 (fr)
JP (1) JP2015524835A (fr)
KR (1) KR20150042841A (fr)
CN (1) CN104684913B (fr)
AP (1) AP2015008325A0 (fr)
AR (1) AR092145A1 (fr)
AU (1) AU2013303993A1 (fr)
BR (1) BR112015003115A2 (fr)
CA (1) CA2881997A1 (fr)
CL (1) CL2015000362A1 (fr)
CU (1) CU20150015A7 (fr)
DE (1) DE102012016908A1 (fr)
EA (1) EA201500232A1 (fr)
HK (1) HK1212327A1 (fr)
IL (1) IL237298A0 (fr)
MA (1) MA37928A1 (fr)
MX (1) MX2015002046A (fr)
NZ (1) NZ704727A (fr)
PE (1) PE20150869A1 (fr)
PH (1) PH12015500322B1 (fr)
SG (1) SG11201501183VA (fr)
TN (1) TN2015000045A1 (fr)
TW (1) TW201412720A (fr)
UA (1) UA112488C2 (fr)
WO (1) WO2014027112A1 (fr)
ZA (1) ZA201501078B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2015121413A1 (fr) * 2014-02-14 2015-08-20 Aicuris Gmbh & Co. Kg Nouvelles combinaisons de principes actifs pharmaceutiques avec des composés à base de tri(hétéro)arylpyrazoles
EP3263567A1 (fr) * 2016-07-01 2018-01-03 AiCuris Anti-infective Cures GmbH Pyrazoles substitués avec une carboxamide et tri(hétéro)aryle-pyrazoles pour utilisation dans le traitement et/ou prévention des maladies cariovasculaires et/ou leurs comorbidités

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6277847B1 (en) 1999-04-02 2001-08-21 Fmc Corporation Herbicidal isoindolinonyl-and 3,4-dihydroisoquinolonyl-substituted heterocycles
CA2465207C (fr) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides et -sulfonamides
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
MXPA05005742A (es) 2002-12-02 2005-08-16 Astellas Pharma Inc Derivados de pirazol utiles como inhibidores de cox-i.
PL377848A1 (pl) 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pochodne pirazoli
CA2555331C (fr) 2004-02-20 2011-01-04 Astrazeneca Ab Agents therapeutiques
SI1732892T1 (sl) 2004-03-26 2009-02-28 Hoffmann La Roche Tetrahidrokarbazoli in derivati
AU2005258397A1 (en) 2004-07-01 2006-01-12 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CA2613522A1 (fr) 2005-06-27 2007-01-04 Exelixis, Inc. Regulateurs de lxr de type imidazole
EP1743637A1 (fr) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés du pyrazole seuls ou en combinaison pour le traitement du syndrome métabolique
ES2326723B1 (es) 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazol sustituidos y combinaciones de los mismos para el tratamiento del sindrome metabolico.
GB0516661D0 (en) 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
EA015034B1 (ru) 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
WO2007064872A2 (fr) 2005-12-01 2007-06-07 Bayer Healthcare Llc Composes de l'uree utilises dans le traitement du cancer
WO2008017932A2 (fr) 2006-08-09 2008-02-14 Pfizer Products Inc. HÉTÉROCYCLES UTILES EN TANT QU'inhibiteurs d'anhydrase carbonique
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
CN101952260B (zh) 2008-02-18 2013-02-13 弗·哈夫曼-拉罗切有限公司 4,5-二氢-*唑-2-基胺衍生物
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP5636428B2 (ja) 2009-09-17 2014-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 置換ｎ−フェニル−１−（４−ピリジニル）−１ｈ−ピラゾル−３−アミン類
US9073940B2 (en) 2009-11-13 2015-07-07 Merck Serono Sa Tricyclic pyrazol amine derivatives
WO2012009009A2 (fr) * 2010-07-14 2012-01-19 Addex Pharma S.A. Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US20130203756A1 (en) 2010-10-29 2013-08-08 Jamie L. Bunda Isoindoline pde10 inhibitors
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2015121413A1 (fr) 2014-02-14 2015-08-20 Aicuris Gmbh & Co. Kg Nouvelles combinaisons de principes actifs pharmaceutiques avec des composés à base de tri(hétéro)arylpyrazoles

Also Published As

Publication number Publication date
CA2881997A1 (fr) 2014-02-20
US9249148B2 (en) 2016-02-02
KR20150042841A (ko) 2015-04-21
TN2015000045A1 (en) 2016-06-29
DE102012016908A1 (de) 2014-02-20
US20150203500A1 (en) 2015-07-23
TW201412720A (zh) 2014-04-01
HK1212327A1 (en) 2016-06-10
CU20150015A7 (es) 2015-11-27
NZ704727A (en) 2016-07-29
EP2885300A1 (fr) 2015-06-24
ZA201501078B (en) 2017-11-29
MX2015002046A (es) 2015-06-05
BR112015003115A2 (pt) 2017-07-04
SG11201501183VA (en) 2015-05-28
PH12015500322A1 (en) 2015-03-30
AU2013303993A1 (en) 2015-03-12
CL2015000362A1 (es) 2015-07-10
AP2015008325A0 (en) 2015-03-31
EA201500232A1 (ru) 2015-07-30
IL237298A0 (en) 2015-04-30
AR092145A1 (es) 2015-03-25
CN104684913B (zh) 2016-11-23
CN104684913A (zh) 2015-06-03
PE20150869A1 (es) 2015-05-27
WO2014027112A1 (fr) 2014-02-20
UA112488C2 (uk) 2016-09-12
JP2015524835A (ja) 2015-08-27
PH12015500322B1 (en) 2015-03-30

Similar Documents

Publication Publication Date Title
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
MA38365A1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA35618B1 (fr) Promédicament de l'adrénomédulline à base de polyéthylène glycol et son utilisation
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA31535B1 (fr) (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
UA112422C2 (uk) Заміщений натрій-1h-піразол-5-олат
MA46235B1 (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
MA38296B2 (fr) Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations
MA37928A1 (fr) Tri(hétéro)arylpyrazoles et leur utilisation
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
CY1117577T1 (el) Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
MA38637B1 (fr) Benzoxazoles substitués